Compare DHF & OSUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DHF | OSUR |
|---|---|---|
| Founded | N/A | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.7M | 214.1M |
| IPO Year | 1998 | 2000 |
| Metric | DHF | OSUR |
|---|---|---|
| Price | $2.38 | $3.14 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 393.1K | ★ 431.4K |
| Earning Date | 01-01-0001 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $167,064,000.00 |
| Revenue This Year | N/A | $4.48 |
| Revenue Next Year | N/A | $7.76 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.22 | $2.08 |
| 52 Week High | $2.63 | $4.22 |
| Indicator | DHF | OSUR |
|---|---|---|
| Relative Strength Index (RSI) | 24.70 | 60.96 |
| Support Level | N/A | $3.05 |
| Resistance Level | $2.62 | $3.31 |
| Average True Range (ATR) | 0.03 | 0.17 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 13.16 | 85.42 |
BNY Mellon High Yield Strategies Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income and its secondary objective is capital appreciation. The fund invests predominantly in fixed-income securities of below-investment-grade credit quality.
OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.